According to a new report published by Allied Market Research, titled, “Organ-tumor-on-a-chip Market by Type: Global Opportunity Analysis and Industry Forecast, 2021–2030," the global organ-tumor-on-a-chip market was valued at $5,937.27 thousand in 2020, and is projected to reach $117,471.41 thousand by 2030, registering a CAGR of 34.3% from 2021 to 2030.
Organ-tumor-on-a-chip is a miniature cell culture device that simulates tumor cell tissue structure and functional units in vitro. Tumor-on-a-chip can be used to simulate tumor growth and expansion, angiogenesis, and progression from early to advanced lesions involving epithelial–mesenchymal transition (EMT), tumor cell invasion and metastasis. Organ-tumor-on-a-chip systems are based on the use of microfluidics to construct tissue models. By using cancer-derived cells and related extracellular matrix (ECMs) in tissue-specific structures to replace those of healthy cells, tumor-on-a-chip systems have emerged.
Recently, organ-tumor-on-a-chip techniques have emerged to recapitulate the microphysiological function and three-dimensional microstructure of in vivo human organs. Organ-on-a-chip devices are microfabricated cell cultures that combine the advantages of microfluidic technology and 3D cell culture technology to mimic the complexity and characteristics of native organs. Organ-tumor-on-a-chip devices possess good performance and improved recapitulation of the native microenvironment, and they allow high‐throughput tests with decreased cost, ethical advantages and enhanced reproducibility. With the development of materials and manufacturing techniques, such as microfluidics and microprinting, combined with stem cell technology, 3D human tissue-like models known as organoids and spheroids are generated. They can be used to research human development, disease progression, and treatment, as well as to develop personalized drug methods.
Organoids are 3D cell culture models that can self-organize into complex organ-like tissues. Organoid models are usually generated from stem cells, including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and adult stem cells. Organoids derived from these stem cells can be integrated into tumor chips, and because of the combination of the two technologies, organ-specific structures and gene expression signatures in vivo could be mimicked better than in either model alone.
A variety of human-derived in vitro tumor-on-a-chip models have been developed for studying various characteristics associated with tumor progression, such as growth, angiogenesis, metastasis, and drug response. By combining advanced microfabrication techniques, such as photolithography, soft lithography and bioprinting, with microfluidic and tissue engineering techniques, tumor chips can ideally reproduce specific key aspects of the tumor microenvironment, such as biochemical gradients and niche factors, dynamic cell–cell and cell–matrix interactions, and complex tissue structures comprised of tumor and stromal cells. Here, we specifically highlight some cancer models with high morbidity and fatality rates, including lung tumor chip, liver tumor chip, brain tumor chip, colorectal-tumor chip, breast tumor chip and pancreatic tumor chip systems.
By type, the lung-tor-on-a-chip segment is the major contributor toward organ-tumor-on-a-chip market growth, owing , owing to rising prevalence in lung cancer cases than any other cancer cases.
In 2020, North America accounted for highest contribution to the total revenue generated, owing to rise in demand for organ-tumor-on-chips in drug screening, especially in the U.S., increase in number of key market players, and research centers in the region.
On ther hand, Asia-Pacific is expected to witness the highest CAGR during the analysis period, high prevalence of cancer cases and rise in geriatric population. Moreover, presence of large number of adoption of organ-tumor-on-a-chip in diagnostics and treatment is expected to boost the organ-tumor-on-a-chip market growth.
The COVID-19 outbreak has impacted the global organ-tumor-on-a-chip negatively. The COVID-19 pandemic has resulted in government authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns which impacted reliable supply of sufficient human cells or a supply at cost effective prices, which harmed the business results of operations The extent to which COVID-19 will impact the future developments, which are highly uncertain and cannot be predicted with confidence, including the rise of vaccine-resistant variants, duration of the outbreak, travel bans, restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. In particular, the continued COVID-19 pandemic adversely impacted various aspects of many company’s operations, including ability to raise additional capital, the timing and ability to pursue the strategy.
The pandemic has also impacted manufacturing and supply chain, sales and marketing and clinical trial operations of potential strategic partners, and the research and development activities and pursue development of the pipeline products adversely.
Key Findings Of The Study
- Depending on type, the lung-tumor-on-a-chip segment segment was highest contributor to the organ-tumor-on-a-chip market in 2020 and is expected to maintain the trend throughout the forecast period attributed to the increasing incidence of lung cancer along with growing demand for lung cancer drug discovery research
- Region wise, Asia-Pacific is expected to exhibit highest CAGR during the forecast period